Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

Publication | Closed Access

DOI

Citations

References

2007

Year

Gershon Y. Locker, Robert E. Mansel, David Cella, Deborah Dobrez, Sonja Sorensen, Sanjay Gandhi

Breast Cancer Research and Treatment

Breast OncologyCost-effectiveness AnalysisMedicineCancer ManagementClinical TrialsGynecologyAnastrozole Versus TamoxifenBreast CancerPharmacotherapyTamoxifen AloneOncologyGynecology OncologyMenopause Hormone Therapy